---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-061383"
form_type: "8-K"
ticker: "CSBR"
cik: "0000771856"
company_name: "CHAMPIONS ONCOLOGY, INC."
filed_at: "2026-09-10T20:46:58+00:00"
generated_at: "2026-09-10T20:48:21.242184+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Champions Oncology Q1 revenue up 8.8% to $15.2M; adjusted EBITDA $671K vs $59K

## Summary
- Revenue $15.2M, +8.8% YoY; oncology services margin improved to 51% from 43%.
- Adjusted EBITDA $671K vs $59K; net loss narrowed to $426K from $466K.
- Sales & marketing expense up 66.6% to $3.1M on commercial expansion.
- Cash $4.4M, no debt; net cash used in ops ~$492K.
- R&D up 12.6% to $2.3M, driven by Corellia share-based compensation.

## SEC filing metadata
- accession: 0001628280-26-061383
- form_type: 8-K
- ticker: CSBR
- cik: 0000771856
- company_name: CHAMPIONS ONCOLOGY, INC.
- filed_at: 2026-09-10T20:46:58+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/771856/000162828026061383/0001628280-26-061383-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/771856/000162828026061383/csbr-20260910.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-061383
- JSON: https://secwatch.observer/filing/0001628280-26-061383.json
- Plain text: https://secwatch.observer/filing/0001628280-26-061383.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.